Exploring Lasofoxifene Plus Abemaciclib in ESR1+ Breast Cancer: Insights from ELAINE-3 With Sagar D. Sardesai, MBBS

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Sagar D. Sardesai, MBBS, about the phase 3 ELAINE-3 trial (NCT05696626) and its evaluation of lasofoxifene in combination with abemaciclib (Verzenio) for patients with ESR1-mutant, estrogen receptor (ER)–positive, HER2-negative locally advanced or metastatic breast cancer. Dr Sardesai is a breast medical oncologist and researcher in the Division of Medical Oncology at The Ohio State University (OSU) and a member of the Cancer Control Program at OSU Comprehensive Cancer Center – James in Columbus.

The trial aims to compare progression-free survival (PFS) outcomes for lasofoxifene plus abemaciclib vs fluvestrant (Faslodex) plus abemaciclib in patients who have previously received a frontline aromatase inhibitor in combination with a CDK4/6 inhibitor other than abemaciclib.

In our exclusive interview, Dr Sardesai provided insights into ELAINE-3's objectives, the challenges of patient enrollment, and the potential implications for lasofoxifene in clinical practice. He emphasized the importance of personalized treatment approaches, especially in patients harboring ESR1 mutations, and how the combination therapy with lasofoxifene and abemaciclib could potentially address the unmet need for effective, targeted therapies.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.